Navigation Links
Watson Announces Pricing of Secondary Offering By Selling Stockholder

MORRISTOWN, N.J., Nov. 11, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced the underwritten public offering of 10,537,755 shares of its common stock held by Quiver Inc. has priced at $49.75 per share.  Watson will not receive any proceeds related to the offering, and its total number of shares of common stock outstanding will not change as a result of the Offering.J.P. Morgan Securities LLC. has acted as sole book-running manager and underwriter for the Offering.

A prospectus supplement relating to the offering has been filed with the Securities and Exchange Commission. Copies of the prospectus supplement and the accompanying base prospectus relating to the Offering may be obtained, when available, by mail from: J.P. Morgan Securities LLC., Attn: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York, 11717, or by phone at (866) 803-9204. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended September 30, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.CONTACTS:Investors:Patty Eisenhaur (973) 355-8141Media:Charlie Mayr(973) 355-8483(Logo:



SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Announces Commencement of Secondary Offering by Selling Stockholder
2. Watson To Present At The 2010 Credit Suisse Healthcare Conference
3. Watson Confirms Crestor® Patent Challenge
4. Watsons Generic Version of Lotrel ® Receives FDA Approval
5. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2010 Earnings
6. Watson Reaches Settlement with Endo Over Opana® ER
7. Watson Confirms Azilect® Patent Challenge
8. Watson to Present at the Jefferies 2010 Global SpecPharma & European Healthcare Conference
9. HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada
10. Watson to Present at the Bank of America/Merrill Lynch Global Healthcare Conference
11. Watsons Generic Yasmin® Receives FDA Approval
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Teledyne DALSA , a ... sensing technology, will introduce its CMOS X-Ray detector for ... November 29 to December 3, at McCormick Place in ... for diagnostic and interventional imaging will be on display in ... of advanced CMOS X-Ray detectors is the industry benchmark ...
(Date:11/24/2015)... , Nov. 24, 2015  Boston Scientific Corporation (NYSE: ... Oppenheimer 26th Annual Healthcare Conference on December 8, in ... Susie Lisa , vice president, Investor Relations, will participate ... beginning at approximately 8:35 a.m. ET. --> ... in a 30-minute question-and-answer session with the host analyst ...
(Date:11/24/2015)...   Renowned UAE ... s advice and insights on supplements and healthy diet ... 50% of Dubai residents are not ...   femMED launches comprehensive solutions for women , ... residents are not consuming enough to keep themselves healthy. A local ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... United ... to welcome Winter-Dent & Company as its newest Partner Firm. Based in Jefferson ... a client's most trusted advisor regardless of whether that client is a business, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for ... with some of the staff members at their recovery center. The videos highlight some ... as some of the things that make their recovery program so unique. , “Making ...
(Date:11/24/2015)... ... 2015 , ... Abington Hospital – Jefferson Health is pleased ... Surgery Facility for treating individuals living with morbid or extreme obesity. , Aetna ... its members to help them make informed decisions about their healthcare needs. In ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty Health Fitness, ... have announced their endorsement of the Medical Fitness Network (MFN), a national health ... have the MFN as one of our endorsed organizations,” said ASH Fitness Vice ...
(Date:11/24/2015)... ... November 24, 2015 , ... World ... Innovative Blending, a household invention that revolutionizes the vending machine industry by providing ... market is worth $2 billion," says Scott Cooper, CEO and Creative Director of ...
Breaking Medicine News(10 mins):